A SOLID
THE PAST & FUTURE
DOLIPRANE:
SANOFI: ATTACKING
BASE FOR
OF THE DOMESTIC
A MOROCCAN
THE CAUSES OF DIABETES
THE REGION
INDUSTRY
EXCEPTION
& MENTAL HEALTH
PAGE 12 12
PAGE 14 14
PAGE 29
PAGE 30
COVER STORY
UNCLOUDED AMBITION Morocco’s High Hopes For Its Pharma Sector page 18
MOROCCO JULY 2015
Zenith pharma, The Dragon of the Moroccan Pharmaceutical Market
Key to this success has been the young and ambitious management team that has been keen to embrace new management techniques, innovative strategies, a nd above all, hard work.
ZenithPharma is an assertive, committed and innovative
Through a combination of high quality service and a strategy of decentralization ZenithPharma has managed to stand out from the crowd – the company is based in the south of Morocco and therefore has benefitted from better access to its customers and great logistics infrastructure.
Moroccan firm that has built a reputation for itself at home through dynamic and remarkable growth. Today, ZenithPharma is ranked in Morocco’s top fifteen pharmaceutical companies, after just eight years in the market.
The philosophy of ZenithPharma is based on audacious assets and open-mindedness: serving the others by providing them comfort and wellbeing. ZenithPharma laboratories strives every day to embrace knowledge and expertise to a nswer every need of Moroccan healthcare professionals and patients by providing high quality, efficient and safe health products.
Résidence les Alizés, la colline 2 n°33 Sidi Maarouf - Casablanca - Maroc Tél : +212 5 22 97 77 30 / Fax : +212 5 22 97 29 14 SIEGE SOCIAL: 96, Zone Industrielle Tassila Inzegane - Agadir - Maroc Tél : +212 5 28 83 83 74 /Fax : +212 5 28 83 79 25
w w w . z e n i t h p h a r m a . m a www.pharmaboardroom.com
Healthcare & Life Sciences Review: Morocco
2
HEALTHCARE & LIFE SCIENCES REVIEW MOROCCO
A Solid Base For The Region Feature 1 2
CONTENTS —July 2015
5
Acknowledgements
6
PREFACE Morocco
8-10 MOROCCO IN FIGURES Industrial Overview / Top Players / Top Drugs
Unclouded Ambition Cover story 18
12
REGIONAL HQs FEATURE Multinationals Speak
14
THE PAST & FUTURE OF THE DOMESTIC INDUSTRY INTERVIEW Abdelilah Lahlou, Iberma
16
MANAGING THE PRICE CUTS INTERVIEW Mehdi Zaghloul, Novartis Morocco
18
MOROCCO
COVER STORY
Unclouded Ambition
20 Shifting Sands: Market Restructuring 21 Getting The Generics Equation Right 22 Why Invest In Morocco? 23 The Gateway To Africa
Doliprane: A Moroccan Exception Feature 29 Feature 29
This edition of Healhcare & Life Sciences Review was produced by Focus Reports. Publisher & Project Director: Julie Director: Julie Avena Written by: Karim by: Karim Meggaro Contributors: Carla Verdera Mateu, Zachary Burnside For exclusive interviews and more info, please log onto www.pharmaboardroom.com or www.pharmaboardroom.com or write to
[email protected].
26
PARTNERSHIPS AND EXPORTS FEATURE Lamia Berrada & Samir Bachouchi, Bottu
29
DOLIPRANE IN MOROCCO Doliprane
30
CSR SPOTLIGHT FEATURE Sanofi, Diabetes And Mental Health
32
RISING STAR INTERVIEW Mohamed El Bouhmadi, ZenithPharma
34
THE INNOVATION GAP INTERVIEW Radia Chmanti Houari, GSK Morocco
36
MOROCCAN M&A INTERVIEW Brahim Oulammou, Promopharm
38
ONCOLOGY IN ACTION Treatment Levels
40
EXPORT OPPORTUNITIES INTERVIEW Driss Chaoui, Afric-Phar
42
PRODUCTION HUB INTERVIEW Myriam Lahlou Filali, Pharma 5 Group
FEATURE
FEATURE
Bottu And
Projects To Improve
Copyright: All rights reserved. No part of this publication publication maybe reproduced in any form or by any means, whether electronic, mechanical or otherwise including photocopying, recording or any information storage or retrieval system without prior written consent of Focus Reports. While every attempt is made to ensure the accuracy of the information contained in this report, neither Focus Reports nor the authors accept any liabilities forerrors and omissions. Opinions expressed in this report are not necessarily necessarily those of the authors.
www.pharmaboardroom.com
Healthcare & Life Sciences Review: Morocco
3
Acknowledgements Acknowledgements PharmaBoardroom would like to thank: The Moroccan Ministry of Health Abdelmajid Abdelmajid Belaiche, Belaiche, Director Director General, General, AMIP AMIP Hubert de Ruty, President, MIS Mohamed Houbachi, President, AMMG Abderrahim Abderrahim Derraji, Derraji, Founde Founder, r, Pharmacie Pharmacie.ma .ma and the industry leaders that we have met for taking the time to share with us their thoughts, their stories and their ambitions. A warm thank you for the support, assistance and enthusiasm we have received from the Moroccan pharmaceutical community. community.
Preface Preface Morocco is too often overlooked as a pharmaceutical nation. However, thanks to decades of experience, the domestic pharmaceutical industry is strong, with a well-developed base of local producers that today manufacture products to high international standards. The quality of local producers in Morocco today is somewhat unknown to the outside world, something we hope to address with this report. Thanks to Morocco’s regional competitiveness, many multinationals have chosen to establish their regional headquarters headquarters in the country, a nod to its political stability, liberal economy and educated workforce. Indeed, in its 2015 Africa Competitiveness Report, the World Economic Forum identified Morocco as the most competitive country in North Africa. One place where the quality of Moroccan pharma is well known is in sub-Saharan Africa. Indeed, Moroccan
6
Healthcare & Life Sciences Review: Morocco
pharma companies have been making inroads as exporters for years now, benefitting from the vision of King Mohammed VI to open Morocco to the south. As well as looking to continue this expansion southwards, many Moroccan companies are now looking at the possibilities beyond Africa – to the north, Europe, and to the west, the US. Quietly, sedately then, Morocco’s pharmaceutical sector is shining. Domestically, with the introduction of new healthcare coverage through the RAMED program, increasing numbers of Morocco’s populace are getting access to medicine; aside from this, manufacturers are improving standards, MNCs are finding new ways to bring innovation to the country, and trade continues to flourish. Morocco’s ambitions in healthcare are clear, and the skies overhead are unclouded.
www.pharmaboardroom.com
EVOLUTION OF MOROCCO’S GDP GROWTH THANKS TO THE DEVELOPMENT OF NEW INDUSTRIAL SECTORS OTHER THAN AGRICULTURE, MOROCCO´S GDP HAS BECOME MORE PREDICTABLE EACH YEAR 15% 13% 11% 9% 7% 5% 3% 1% 0 -1% -3% -5% -7% 0 9 9 1
1 9 9 1
2 9 9 1
3 9 9 1
4 9 9 1
5 9 9 1
6 9 9 1
7 9 9 1
8 9 9 1
9 0 9 0 9 1 2 0
1 2 0 0 0 2 2 0
MOROCCO BY THE NUMBERS
2
1 0 0 2
1 1 2 0
2 1 0 2
3 1 2 0
THE GOBAL COMPETITIVENES COMPETITIVENESS S INDEX 2014—2015
LOCAL PRODUCTION COVERS
69.4 33
nd
COUNTRY/REGION: COUNTRY /REGION: NORTH AFRICA
Rank
Value
NO R T H AFRICAN AVERAGE
%
LARGEST PHARMA SECTOR IN AFRICA BY SIZE (AFTER SOUTH AFRICA)
OF DOMESTIC DEMAND
7-8
S S E N E 5 V I 1 T I 0 T 2 E P 4 M 1 O 0 C 2
AN INCREASE OF
21.7
%
%
OF ITS PRODUCTION
IN TURNOVER 2012-13
S E X E D N I B U S
THE MOROCCAN MARKET MARKET SIZE: USD
USD
1.51 0.89 4 BILLION TOTAL
MOROCCO ALGER I A
TUNI S IA
EGY P T
LI BYA
72
79
87
1 19
1 26
4. 21
4 . 08
3 .96
3 . 60
3 .4 8
57
65
85
121
1 11
4 .74
4 .6 4
4. 38
3 .7 3
3 . 86
78
125
94
106
1 37
3 . 92
3 . 34
3 .74
3 . 58
3 .0 3
82
13 3
93
113
14 3
3 50
2 . 91
3 .4 0
3 .1 8
2 . 49
INDUSTRIAL UNITS
MOROCCO EXPORTS
BILLION PRIVATE MARKET
%
EXPECTED CAGR 2013-18
Source: IMS Health, AMIP
8
7 3 5 8 6 9 4 0 0 0 0 0 0 0 0 0 0 0 2 0 2 0 2 2 0 2 2 2
Healthcare & Life Sciences Review: Morocco
S T N E M E R I C I U S Q A E B R
S Y R C E N C E N I C A I F H F N E E
N O I & T N A C O I I T T S R A S I V O T O H P N O C A N I S F
3.87
4.27
3.52
3.09
Source: World Economic Forum
www.pharmaboardroom.com
MOROCCO IN FIGURES Top Players
EVOLUTION OF THE PRIVATE PHARMA MARKET IN VALUE
TOP 10 LABORATORIES IN VALUES IN 2013
UNITS: Billion USD
1
2
SANOFI-AVENTIS
0.89
4
0.87
0.88
MAPHAR
6
0.83
BOTTU
0.80
8
GALENICA
2010
2011
2012
Source: AMIP
2013
2014
Exchange rate: rate: USD 1 = MAD 10
GENERIC AND ORIGINATORS IN UNITS AND VALUES IN 2013
UNITS IN 2013 (IN THOUSANDS OF UNITS)
MOROCCO
G E N E RIC S
ORIGINATORS
307,426 .6
97, 8 56 .9
20 9, 56 9.7
10
1. 5
4.1
VALUE IN 2013 (IN USD MILLION) EVOLUTION 2012—2013 % IN VALUE
10 10 0.0
2
4
68.2
6
2.6
10 0.0
298,771
6 .7
598 ,8 57
0.7
3 3. 3
GSK
9
NOVARTIS
1
GALENICA
897,629
7
TOP 10 LABORATORIES IN UNITS PRODUCED IN 2013
0.4
31 . 8
5
LAPROPHAN
Source: IMS Health
SOTHEMA
% IN UNITS
3
COOPER MAROC
PFIZER MAROC
COOPER MAROC
EVOLUTION 2012—2013
SOTHEMA
8
PHARMA 5
10
66 .7
BOTTU
3
MAPHAR
5
LAPROPHAN
7
SANOFI-AVENTIS
9
BAYER MAROC
GSK
Source: IMS Health
www.pharmaboardroom.com
Exchange rate: USD 1 = MAD 10
Source: IMS Health
Healthcare & Life Sciences Review: Morocco
9
TOP 10 THERAPEUTIC CLASSES IN UNITS (2013) Therapeutic classes in values
Market share in % of value
Source: IMS Health 18.3%
15.4%
11.9%
APP DIGESTIVE METABOLISM
11.0%
GENERAL ANTIINFECTIVES NERVOUS SYSTEM
8.0%
APP CARDIOVASCULAR
7.6%
BREATHING APPARATUS
12.0%
7.1%
MUSCULOSKELETAL SYSTEM APP GENIT- URIN.HORM.SEX DERMATOLOGY
4.5% 4.0%
SENSE ORGANS OTHERS
TOP 10 MEDICINES IN MOROCCO BY VOLUME, 2014
DOLIPRANE ®
DOLIPRANE ®
AUREOMYCINE AUREOMYCINE ®
AUGMENTIN ®
MICRODIOL ® MINIDRIL ®
OEDES ® MICRODIOL ®
ASPRO ®
AMOXIL ®
COQUELUSÉDAL ®
ERECTOR ®
RINOMICINE ®
CLAVULIN ®
ADEPAL ®
VENTOLINE ®
PERNABOL ®
SURGAM ®
AMOXIL ®
ACLAV ®
Source: IMS Health
10
TOP 10 MEDICINES IN MOROCCO BY SALES, 2014
Healthcare & Life Sciences Review: Morocco
Source: IMS Health
www.pharmaboardroom.com
www.pharmaboardroom.com
Healthcare & Life Sciences Review: Morocco
11
